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ABSTRACT
Background: The objective of this study was to establish the efficacy and safety of procalcitonin 
(PCT)-guided antibiotic discontinuation in critically ill patients with sepsis in a country with a 
high prevalence of antimicrobial resistance and a national health insurance system.
Methods: In a multi-center randomized controlled trial, patients were randomly assigned 
to a PCT group (stopping antibiotics based on a predefined cut-off range of PCT) or a 
control group. The primary end-point was antibiotic duration. We also performed a cost-
minimization analysis of PCT-guided antibiotic discontinuation.
Results: The two groups (23 in the PCT group and 29 in the control group) had similar 
demographic and clinical characteristics except for need for renal replacement therapy on 
ICU admission (46% vs. 14%; P = 0.010). In the per-protocol analysis, the median duration of 
antibiotic treatment for sepsis was 4 days shorter in the PCT group than the control group (8 
days; interquartile range [IQR], 6–10 days vs. 14 days; IQR, 12–21 days; P = 0.001). However, 
main secondary outcomes, such as clinical cure, 28-day mortality, hospital mortality, and 
ICU and hospital stays were not different between the two groups. In cost evaluation, PCT-
guided therapy decreased antibiotic costs by USD 30 (USD 241 in the PCT group vs. USD 
270 in the control group). The results of the intention-to-treat analysis were similar to those 
obtained for the per-protocol analysis.
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Conclusion: PCT-guided antibiotic discontinuation in critically ill patients with sepsis could 
reduce the duration of antibiotic use and its costs with no apparent adverse outcomes.
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INTRODUCTION
The duration of antibiotic therapy in critically ill patients with sepsis is currently based on 
empirical rules depending on the severity of the patients' clinical condition and the site 
of infection.1 As a result of the lack of clear guidance in difficult clinical situations dealing 
with septic patients, however, there is an inherent tendency for antibiotic overuse in the 
intensive care unit (ICU).2 In addition, clinicians may be reluctant to shorten the duration 
of antibiotic therapy in patients with sepsis.3 These factors could increase the risk of 
developing antimicrobial resistance and treatment-related costs.4 Use of a biomarker of 
resolution of infection could assist clinicians in making the decision to discontinue empiric 
antibiotics.1 Among sepsis biomarkers, procalcitonin (PCT), a precursor of calcitonin, has 
been most widely studied to guide antibiotic therapy in patients with sepsis.5-15 Data from 
randomized-controlled trials confirms the safety and efficacy of PCT-guided discontinuation 
of antibiotics in patients with sepsis.6-13 However, most of these studies were conducted in 
western countries with a relatively low consumption of antibiotics16 and a low prevalence 
of antimicrobial resistance17 compared to Asian countries. In addition, data on the cost-
effectiveness of PCT-guided antibiotic therapy are difficult to generalize to countries with 
public insurance systems,11,13 because insured patients are less affected by antibiotic costs.4
In Korea, which has a compulsory national health insurance system, prevalence of 
antimicrobial resistance to major bacterial pathogens has increased gradually.18 Therefore, 
the Korean National Evidence-based Healthcare Collaborating Agency organized a study 
group on issues regarding efficacy, safety, and cost-effectiveness of PCT-guided antibiotic 
therapy in critically ill patients with sepsis. The objectives of this study were to assess the 
efficacy and safety of PCT-guided antibiotic therapy in critically ill patients with sepsis in 
a country with a high prevalence of antimicrobial resistance, and to perform an economic 
evaluation in the context of a national health insurance system.
METHODS
Study design and participants
This prospective, single-blinded, randomized, controlled, investigator-initiated trial on 
the duration and cost of antibiotic treatment for sepsis in the ICU (PROcalcitonin-guided 
treatment on Duration of Antibiotic therapy and cost in septic patients: PRODA) was conducted 
in four medical ICUs in Korea. To be eligible, patients had to be older than 18 years of age, 
enrolled within 24 hours of admission to ICU with suspected severe sepsis or septic shock, 
and expected to remain in the ICU for longer than 48 hours if they had received antibiotics for 
less than 48 hours. Exclusion criteria were patients with proven bacterial infection requiring 
more than 3 weeks' antibiotic therapy; antibiotic therapy started 48 hours or more before 
enrollment; severely immunocompromised patients, such as patients infected with human 
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immunodeficiency virus and with a CD4 count of less than 200 cells/mm3, neutropenic patients 
(< 500 neutrophils/mm3), or patients on immunosuppressive therapy; subjects not expected to 
survive to hospital discharge or those with do-not-resuscitate orders; or known pregnancy.
Interventions
Prospective written informed consent was obtained from all patients or legally authorized 
representatives. Patients were randomly assigned at a 1:1 ratio to PCT-guided or clinician-
guided groups. A computer-generated randomization list in blocks of four was used 
for treatment allocation. Randomization procedure and allocation of treatment were 
performed by the research coordinator. The sequence was concealed from patients and 
investigators until interventions were assigned. However, investigators were aware of 
treatment assignment after randomization. Investigator and the coordinators were unaware 
of outcomes during the study, and primary endpoints were strictly defined and not patient-
reported. Data were collected by professional research personnel at each site.
All patients included in the study had their serum PCT concentration measured at baseline 
as close to initiation of antibiotics as possible. For patients randomly assigned to the PCT-
guided group, measurements of PCT concentrations were taken every other day until day 14 
after inclusion or until antibiotics were stopped. The study protocol advised discontinuation 
of prescribed antibiotics if PCT concentration had decreased by 80% or more of its peak 
value (relative stopping threshold) or when it reached a value of 0.5 µg/L or lower (absolute 
stopping threshold) based on a previously published algorithm.9,13 Of note, the final 
decision concerning the duration of antibiotic use was left to the discretion of the attending 
physician. Cases in whom antibiotic therapy was continued despite the encouragement 
of the investigators to stop it were classified as ‘overruling’ and the reasons for overruling 
were recorded. For patients assigned to the clinician-guided group, the investigators did not 
interfere with the duration of antibiotic therapy.
For both groups, antibiotic selection was at the discretion of the attending physicians. 
Nevertheless, broad-spectrum antibiotics were recommended for initial empirical 
treatment (i.e., before the susceptibility patterns of the responsible pathogens became 
known) of sepsis. Antibiotic de-escalation with narrower-spectrum antibiotics was strongly 
recommended on the basis of culture results when possible.
Outcomes
The primary endpoint was the duration of antibiotic therapy, expressed as days between start and 
end of antibiotics in the two groups for all randomized patients who were not excluded (modified 
intention-to-treat population). Secondary endpoints were the percentage of patients who had a 
cure or recurrence of the initial infection, 28-day mortality, in-hospital mortality, length of stay 
in ICU and hospital, and costs of antibiotics and care for sepsis. The costs of care for individual 
patients were obtained via a fee-for-service based costing system that extracted all information 
relating to the clinical procedures performed on each patient during the study period. However, 
this information was available for only two of the four participating hospitals (Seoul National 
University Hospital and Samsung Medical Center). Economic evaluation examined whether the 
PCT-guided strategy was cost-effective compared to the clinician-guided group. We constructed 
a cost-minimization approach because mortality, which is a major clinical outcome in this 
population, was not significantly different between the PCT-guided group and clinician-guided 
group in this study. A healthcare system perspective that includes medical and non-medical 
costs was employed. Regarding medical costs, hospitalization costs to care for sepsis paid by the 
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national health insurance and copayments by patients were included. We did not consider non-
medical costs, such as time or transportation costs, because our study population comprised 
hospitalized sepsis patients. Costs were not discounted as the time horizon was the period of 
hospitalization. To facilitate comparison of outcomes with other countries, total costs were 
expressed in US dollars based on an exchange rate of 1,010.98 Korean Won/USD, which was the 
existing exchange rate at the time of initiation of the study (July 1, 2014).
Statistical analysis
The goal of this study was to establish whether a PCT-guided strategy was superior to a 
clinician-guided strategy in terms of antibiotic duration and cost-effectiveness, and to 
demonstrate the non-inferiority of PCT-guided antibiotic therapy with regard to recurrent 
infections. We assumed mean durations of 14 days of antibiotic therapy in the control group 
and 9 days in the PCT group, and a standard deviation of 5 days in both groups based on data 
from previous studies6,19 and Korean antibiotic consumption characteristics.20 To assess the 
superiority of the primary outcome with an α error of 0.05 and a power of 80%, we calculated 
that we needed to enroll at least 23 patients in each group to detect a 36% (five days) 
difference in duration of antibiotic therapy for the initial infection between the two groups. 
Assuming a 10% drop-out rate, we planned enrollment of 50 subjects.
Continuous data are presented as medians with interquartile ranges (IQRs) while categorical 
variables are presented as numbers and percentages. Data were compared using the Mann-
Whitney U test for continuous variables and Pearson's χ2 test or Fisher's exact test for categorical 
variables. The Kaplan-Meier method was used to estimate the cumulative rates of antibiotic 
cessation, which were subsequently compared using the log-rank test. Primary endpoints were 
first analyzed on the basis of modified intention-to-treat analysis for all randomized patients 
who were not excluded. Then, we performed a per-protocol analysis excluding patients who 
did not follow the PCT algorithm and patients who died before a decision to stop antibiotics 
could be taken, because this was the targeted population in this study (i.e., patients in whom a 
decision to stop antibiotics could be taken on the basis of the PCT levels) (Fig. 1). For economic 
evaluation of PCT-guided antibiotic therapy, we performed a cost-minimization analysis. To 
evaluate the cost-effectiveness of the PCT-guided therapy, we compared the total cost per patient 
with sepsis by cumulating the hospital costs including general ward and ICU stay, antibiotic 
treatment cost, and PCT cost. Each cost was the multiplication of the mean daily costs per 
patient. All tests were two-sided, and P < 0.05 was considered significant. Data were analyzed 
using SAS version 9.4 (SAS Institute Inc. Cary, NC, USA).
Ethics statement
The study protocol was approved by The Institutional Review Board (IRB) of National 
Evidence-based Healthcare Collaborating Agency, Ministry of Health and Welfare, Korea (IRB 
No. 14-081-1), and the ethics committees of all participating sites. The study was monitored 
by an independent data safety and monitoring committee, with no interim analysis 
performed. This study was registered at ClinicalTrials.gov under the identifier NCT02202941.
RESULTS
Study population
From July 2014, through June 2015, 382 patients were assessed for eligibility. Of these, 62 
(16%) patients were enrolled, including nine patients who needed long-term antibiotic 
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therapy, transferred to other hospital, or withdrew from the study, resulting in a modified 
intention-to-treat population of 53 patients (23 in the PCT group and 29 in the control 
group, Fig. 1). Baseline characteristics of all included patients are shown in Table 1. The 
two groups had similar demographic and clinical characteristics except for need for renal 
replacement therapy on ICU admission (46% in the PCT group vs. 14% in the control 
group; P = 0.010). Similar proportions of patients with community-acquired, healthcare-
associated, and hospital-acquired sepsis were included in both groups. Forty-eight percent 
of patients in the PCT group required vasopressor support as compared with 55% of those in 
the control group (P = 0.707).
The rate of microbiologically confirmed sepsis did not differ significantly between the two 
groups (96% in the PCT group vs. 97% in the control group; P = 0.891). Blood cultures were 
positive in 71% of patients in the PCT group and 66% of patients in the control group (P = 
0.680). Occurrence of multi-drug resistant pathogens was not significantly different between 
the two groups (17% in the PCT group vs. 3% in the control group; P = 0.164), and the 
majority of patients were administered adequate antibiotics in both groups (Table 1).
Median PCT levels on enrollment were similar in both groups (24.7 µg/L, IQR, 8.5–55.4 µg/L 
in the PCT group; 26.8 µg/L, IQR, 4.8–48.2 µg/L in the control group; P = 0.665). Other 
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382 patients assessed for eligibility
62 enrolled and randomized
23 included in the modified
intention-to-treat analysis
29 included in the modified
intention-to-treat analysis
26 included in the per
protocol analysis
11 included in the per
protocol analysis
30 procalcitonin-guided group 32 clinician-guided group
3 excluded
  2 needed long-term antibiotics
  1 non-bacterial pathogen
12 excluded
  10 overruled
  2 died with antibiotics
7 excluded
  2 needed long-term antibiotics
  2 transferred
  2 withdrew informed consent
  1 non-bacterial pathogen
320 excluded
  100 > 48 hours of antibiotics
  57 severely immunocompromised
  40 do-not-resuscitate orders
  16 long-term antibiotic therapy needed
  16 refused consent
  91 others
3 excluded
  3 died with antibiotics
Fig. 1. Flow chart of the screening and randomization process.
inflammatory markers, including leukocytosis and C-reactive protein level, did not differ 
between the two groups (Table 1).
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Table 1. Baseline characteristics of the septic patients
Characteristics Modified intention-to-treat analysis Per-protocol analysis
Procalcitonin group 
(n = 23)
Control group  
(n = 29)
P value Procalcitonin group 
(n = 11)
Control group  
(n = 26)
P value
Age, yr 69 (61–75) 70 (63–77) 0.537 69 (63–74) 71 (61–77) 0.781
Gender, men 8 (33) 14 (48) 0.272 4 (36) 12 (46) 0.723
Comorbidities
Diabetes 13 (54) 11 (38) 0.237 6 (55) 9 (35) 0.295
Cardiovascular disease 7 (29) 8 (28) 0.899 3 (27) 6 (23) > 0.999
Chronic lung disease 6 (25) 7 (24) 0.942 3 (27) 5 (19) 0.672
Chronic renal disease 8 (33) 7 (24) 0.459 4 (36) 5 (19) 0.404
Chronic liver disease 6 (25) 4 (14) 0.482 2 (18) 4 (15) > 0.999
Malignancy 5 (21) 7 (24) 0.775 2 (18) 6 (23) > 0.999
Charlson comorbidity index 4 (2–5) 3 (2–4) 0.301 2 (2–4) 3 (2–4) 0.919
Acquisition of infection 0.387 0.293
Community-acquired 9 (37) 14 (48) 4 (36) 14 (54)
Healthcare-associated 9 (37) 10 (35) 4 (36) 8 (31)
Hospital-acquired 6 (25) 5 (17) 3 (27) 4 (15)
Sites of infection 0.927 0.908
Pulmonary 5 (21) 10 (35) 2 (18) 8 (31)
Intraabdominal 8 (33) 11 (38) 5 (46) 11 (42)
Urinary 9 (38) 4 (14) 3 (27) 4 (15)
Skin and soft tissue 1 (4) 0 0 0
Catheter-related 0 0 0 0
Others 1 (4) 3 (10) 1 (9) 2 (8)
Unknown 0 1 (3) 0 1 (4)
Bacterial pathogen identified 12 (52) 15 (52) 0.560 5 (45) 13 (50) 0.543
Gram positive pathogens
S. pneumoniae 1 0 0 0
Enterococcus 1 1 1 0
Methicillin-resistant S. aureus 1 1 1 1
Other gram positive bacteria 0 1 0 1
Gram negative pathogens
P. aeruginosa 1 0 0 0
K. pneumoniae 2 3 1 3
E. coli 5 6 1 5
Enterobacter species 0 3 1 3
Other gram negative bacteria 1 0 0 0
MDR pathogen 4 (17) 1 (3) 0.164 2 (18) 1 (4) 0.205
Appropriateness of empirical antibiotics 0.748 0.646
Appropriate 20 (83) 22 (76) 10 (91) 21 (81)
Inappropriate 1 (4) 1 (3) 0 0
Not available 3 (13) 6 (21) 1 (9) 5 (19)
Clinical status on ICU admission
Need for MV 9 (38) 12 (41) 0.774 5 (46) 10 (39) 0.728
Need for vasopressor support 12 (50) 16 (55) 0.707 4 (36) 14 (54) 0.331
Need for RRT 11 (46) 4 (14) 0.010 5 (46) 2 (8) 0.016
Corticosteroids 6 (25) 8 (28) 0.832 1 (9) 6 (23) 0.649
Laboratory findings
White blood cells, ×103/µL 15.9 (12.3–30.8) 15.8 (9.8–24.5) 0.353 12.7 (9.7–17.5) 14.9 (9.2–24.9) 0.658
Procalcitonin, µg/L 24.7 (8.5–55.4) 26.8 (4.8–48.2) 0.665 19.5 (4.7–42.1) 28.1 (6.3–50.0) 0.727
C-reactive protein, mg/dL 17.2 (6.6–27.9) 15.5 (7.9–26.9) 0.962 18.1 (7.7–23.8) 16.8 (9.4–30.1) 0.653
Lactate, mmol/L 4.3 (1.5–7.0) 2.7 (1.6–4.6) 0.289 3.9 (1.3–6.9) 2.8 (1.7–4.5) 0.506
Severity of illness
APACHE II 28 (17–38) 21 (16–31) 0.168 31 (20–32) 20 (16–28) 0.101
SOFA score 10 (5–14) 9 (7–11) 0.490 10 (7–11) 9 (6–11) 0.481
Data are presented as medians (interquartile ranges) or number (%).
ICU = intensive care unit, APACHE II = Acute Physiology and Chronic Health Evaluation II, SOFA = Sequential Organ Failure Assessment.
Main outcomes
In the modified intention-to-treat population, the median antibiotic duration for the first 
episode of sepsis was 3 days shorter in the PCT group (10 days; IQR, 8–14 days) than in the 
control group (13 days; IQR, 10–21 days), although this difference did not achieve statistical 
significance (P = 0.078). However, cumulative rate of antibiotic cessation was significantly 
higher in the PCT group than in the control group (P = 0.029, log rank test) (Fig. 2A). The rate 
of clinical cure was not different between the two groups (83% in the PCT group vs. 79% in 
the control group; P = 0.858). Mortalities at Day 28 and in-hospital were also not significantly 
different between the two groups (Table 2). In addition, lengths of ICU and hospital stays 
were not different between the two groups.
In the PCT group, recommendations for antibiotic cessation were not followed in 10 
patients. In addition, five patients died before a decision regarding antibiotic cessation 
could be taken (2 in the PCT group, 3 in the control group). The remaining 11 of 23 (48%) 
patients in the PCT group and 26 of 29 (90%) patients in the control group completed their 
antibiotic therapy: these two groups were compared as per-protocol analysis (Fig. 1). Similar 
to the modified intention-to-treat analysis, the two groups were balanced according to 
baseline characteristics except for the need for renal replacement therapy on ICU admission 
(Table 1). Patients strictly treated according to the PCT-guided protocol (excluding patients 
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Fig. 2. Probability of antibiotic cessation in patients with sepsis. Kaplan-Meier estimates of the probability of antibiotic cessation in the intention-to-treat 
population (A, P = 0.029 for log rank test) and the per-protocol population (B, P < 0.001 for log-rank test). Solid line represents the procalcitonin-guided group 
and the dotted line represents the control group.
Table 2. Primary and secondary outcome measures according to modified intention-to-treat analysis
Variables Procalcitonin group  
(n = 23)
Control group  
(n = 29)
P value
Primary outcome
Duration of antibiotic therapy, day 10 (8–14) 13 (10–21) 0.078
Secondary outcomes
Clinical cure 20 (83) 23 (79) 0.858
Recurrence of the first episode of infection 0 0 -
28-day mortality 4 (17) 6 (21) 0.709
In-hospital mortality 6 (25) 7 (24) 0.942
Length of ICU stay, day 4 (3–8) 5 (3–8) 0.588
Length of hospital stay, day 21 (11–29) 19 (10–29) 0.796
Data are presented as medians (interquartile ranges) or number (%).
ICU = intensive care unit.
who had the algorithm overruled) had a significantly shorter median duration of antibiotic 
therapy than those in whom the protocol was not followed (8 days; IQR, 6–9 days vs. 16 days; 
IQR, 12–21 days; P < 0.001). Overall, the median duration of antibiotic therapy was significantly 
reduced in patients randomized to the PCT group compared with controls (8 days; IQR, 
6–10 days vs. 14 days; IQR, 12–21 days; P = 0.001). Cumulative rate of antibiotic cessation was 
significantly higher in the PCT group than in the control group (P < 0.001, log-rank test) (Fig. 
2B). Main secondary outcomes, such as clinical cure, 28-day mortality, hospital mortality, and 
ICU and hospital stays were comparable in the two groups (Table 3).
Economic evaluation
In the modified intention-to-treat analysis, the mean daily costs per patient in the ICU were 
not significantly different; $1,128 (SD, $387; IQR, $947–$1,418) in the PCT group and $824 
(SD, $589; IQR, $415–$824) in the control group (P = 0.134). Similarly, the mean daily costs 
per patient in the general ward were $410 (SD, $324; IQR, $205–$516) in the PCT group 
and $340 (SD, $333; IQR, $154–$491) in the control group (P = 0.660) (Table 4). The total 
cumulative estimated cost was higher in the PCT group than the control group by $2,842, 
where that of the PCT group and control group were $11,721 and $8,879, respectively. 
However, PCT-guided therapy reduced antibiotic costs by $30 ($241 in the PCT group vs. 
$270 in the control group) (Table 5).
The results from the per-protocol analysis showed similar trends to those obtained from the 
intention-to-treat analysis. The mean daily costs per patient in the ICU were $955 (SD, $421; 
IQR, $617–$1,252) in the PCT group and $700 (SD, $488; IQR, $402–$778) in the control group 
(P = 0.283), while the costs in the general ward were $506 (SD, $249; IQR, $418–$590) in the 
PCT group and $382 (SD, $328; IQR, $173–$543) in the control group (P = 0.461). Although the 
PCT group was not more cost-effective than the control group in the per-protocol analysis, the 
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Table 3. Primary and secondary outcome measures according to per-protocol analysis
Variables Procalcitonin group  
(n = 11)
Control group  
(n = 26)
P value
Primary outcome
Duration of antibiotic therapy, day 8 (6–9) 14 (10–22) < 0.001
Secondary outcomes
Clinical cure 10 (91) 23 (85) 0.829
Recurrence of the first episode of infection 0 0 -
28-day mortality 1 (9) 3 (12) > 0.999
In-hospital mortality 1 (9) 4 (15) > 0.999
Length of ICU stay, day 4 (4–7) 5 (3–8) 0.523
Length of hospital stay, day 17 (10–29) 21 (12–33) 0.454
Data are presented as medians (interquartile ranges) or number (%).
ICU = intensive care unit.
Table 4. Mean daily costs per patient with sepsis
Variables Modified intention-to-treat analysis Per-protocol analysis
Procalcitonin group 
(n = 23)
Control group  
(n = 29)
P value Procalcitonin group 
(n = 11)
Control group  
(n = 26)
P value
Hospital costs
General ward 410 ± 324 340 ± 333 0.660 506 ± 249 382 ± 328 0.461
ICU stay 1,128 ± 387 824 ± 589 0.134 955 ± 421 700 ± 488 0.283
Treatment
Antibiotics 24 ± 16 21 ± 25 0.177 26 ± 20 18 ± 22 0.358
All medical costs are presented in U.S. dollars. Data are presented as mean ± standard deviation.
ICU = intensive care unit.
antibiotic cost was lower in the PCT group by $53 ($206 in the PCT group vs. $259 in the control 
group) (Table 4).
DISCUSSION
In the PRODA trial, we observed a significant reduction in antibiotic duration in critically 
ill patients with sepsis for whom a decision could be made to discontinue antibiotic use 
based on an analysis of serial PCT measurements using an algorithm (per-protocol analysis). 
Early discontinuation of antibiotics based on the PCT-guided protocol was non-inferior to 
standard care with respect to outcomes. In addition, PCT-guided antibiotic therapy decreased 
antibiotic costs by 20%.
PCT is the prohormone precursor of calcitonin that is expressed primarily by C cells of 
the thyroid gland. PCT is produced ubiquitously in response to endotoxins or mediators 
released in response to bacterial infections and is strongly correlated with the extent and 
severity of bacterial infections.21 Therefore, PCT is primarily used to establish the presence 
of bacterial infection.22 Furthermore, because serum PCT level halves daily when infection 
is controlled, PCT can be used to monitor disease course and response to treatment.23 The 
current Surviving Sepsis Campaign Guidelines also suggest that PCT level can be used to 
support shortening the duration of antibiotic therapy in sepsis patients, with a low quality of 
evidence.24 However, clinical experience with antimicrobial stewardship based on PCT level 
is limited25 and the potential for harm remains a concern, especially in critically ill patients.14
To the best of our knowledge, eight randomized controlled trials assessing the efficacy of 
PCT-guided discontinuation of antibiotics in ICU patients with sepsis have been published.6-13 
These studies have addressed whether it is possible to stop antibiotic treatment based on a 
PCT-guided strategy in critically ill patients, although the strategies differed among the studies. 
A landmark study by Nobre et al.6 showed that a PCT-guided strategy was able to reduce the 
duration of antibiotic treatment for sepsis. This strategy was supported by subsequent studies 
conducted in surgical ICUs,7,8 although because these were single center studies with a relatively 
small sample of patients, the generalizability of their findings is limited. A subsequent large 
multi-center PRORATA study showed that a PCT-guided strategy to treat suspected bacterial 
infections in non-surgical patients in the ICU could reduce antibiotic exposure.9 However, this 
previous study evaluated a PCT-guided strategy that included decisions on when to initiate 
antibiotic treatment, in contrast to other recent trials, including our study. In addition, the 
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Table 5. Total cumulative costs per patient with sepsis
Variables Modified intention-to-treat analysis Per-protocol analysis
Procalcitonin group 
(n = 23)
Control group  
(n = 29)
Procalcitonin group 
(n = 11)
Control group  
(n = 26)
Hospital costs
General ward 6,968.1 4,758.1 6,572.9 6,117.5
ICU stay 4,510.1 4,121.3 3,818.4 3,500.7
Treatment
Antibiotics 240.5 270.1 206.2 258.8
Laboratory test
PCT 242.8 - 207.3 -
Total cost 11,721.0 8,879.4 10,598.6 9,618.2
All medical costs are presented in U.S. dollars.
ICU = intensive care unit, PCT = procalcitonin.
PRORATA study was an open-label trial, which raises the possibility that treatment bias might 
have occurred. Subsequent RCTs were unable to confirm that a PCT-guided strategy may 
significantly reduce the duration of antibiotic treatment in patients with non-microbiologically 
proven apparent sepsis10 or in patients with proven bacterial infection.11 Furthermore, the 
relatively large multi-centre ProGUARD study conducted by the ANZICS clinical trials group 
also showed no significant reduction in duration of antibiotic treatment, antibiotic-free days, 
or overall antibiotic exposure between a standard care group and a PCT-guided group.12 Unlike 
previous studies, the majority of investigators in that study used a PCT cut-off of < 0.1 µg/L 
for antibiotic cessation. Evaluating PCT distribution over time, the majority of patients did 
not meet the cut-off of < 0.1 µg/L until they were beyond 7 days of antibiotic treatment. This is 
further supported by a reported adherence rate to the protocol of 97%. Hence, given the strict 
stopping rule of that study, it is conceivable that clinicians who were adherent to the protocol 
continued antibiotic therapy. Another confounding point may have been the availability of an 
antimicrobial stewardship strategy that was available for the standard therapy arm, which was 
not present in the other studies presented. The most recent and largest multi-center pragmatic 
SAPS study of 1,575 critically ill patients with suspected infection in which the algorithm 
to stop antibiotics was similar to PRORATA demonstrated a reduction in both antibiotic 
exposure and mortality.13 As in PRORATA, however, around 50% of physicians did not adhere 
to the recommendation to stop antibiotic treatment. Despite the strength of the evidence 
described above, it is unclear how generalizable the findings from Western countries are to 
Asian countries, including Korea. Our study provides additional evidence that a reduction in 
antibiotic exposure can be achieved without an increase in morbidity or mortality when using 
PCT-guided antibiotic therapy in a different environment to that in Western nations. However, 
the use of PCT as well as its impact outside of the clinical trial setting should be evaluated,26 
because compliance with PCT algorithms is associated with decreased antibiotic duration 
without increased adverse events.27
Several studies have suggested that PCT-guided antibiotic therapy could result in a total costs 
saving due to a reduction in ICU and hospital length of stays, as well as a reduction in the 
duration of antibiotic therapy.28-30 However, cost-effectiveness was not evaluated in detail in 
the previously published randomized controlled trials. In the SAPS study,13 the costs for the 
first course of antibiotics were reduced due to a reduction in antibiotic duration and cost, but 
cost-effectiveness was not evaluated. In the present study, where we used a cost-minimization 
approach, PCT-guided antibiotic therapy did not reduce overall treatment-related costs but it 
did reduce antibiotic therapy-related costs. It is difficult to explain this result; however, this may 
be due to the different proportions of patients that required renal replacement therapy on ICU 
admission in the two groups. It was announced on June 1, 201731 that the PCT test for sepsis 
management will be reimbursed by the National Health Insurance Service of Korea based on the 
results of the present study and a budget impact analysis of reimbursements (data not shown).
This study is the first randomized controlled study conducted in a non-Western country to 
determine the efficacy and safety of PCT-guided antibiotic therapy in critically ill patients 
with sepsis. A strength of our study is that we performed cost-effectiveness analysis of 
PCT-guided antibiotic therapy in Korea, which has a compulsory national health insurance 
system. However, several limitations of the study should be acknowledged. First, our study 
population was representative of severely ill patients with sepsis with a higher severity of 
illness than in previous reports. In addition, no surgical patients were included in this study. 
Therefore our findings cannot be extrapolated to surgical patients in whom PCT might be 
elevated even in the absence of infection.32 In addition, we cannot exclude a potential harm 
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of shortening antibiotic treatment based on PCT level given the relatively small number of 
patients enrolled, although we did not find any differences in secondary outcomes between 
the two groups. Second, cost data were available from only two hospitals. Even though the 
characteristics of the patients registered at each hospital were similar, clinicians' treatment 
patterns could have differed among the hospitals. Finally, antibiotics were not stopped 
despite the recommendation to stop antibiotic treatment in 43% of patients in the PCT 
group, which is consistent with other major trials on PCT guided antibiotic treatment.9,13 
Despite its limitation, the cumulative rate of antibiotic cessation was significantly reduced, 
indicating that especially inappropriate antibiotics were the first to be discontinued, which 
might turn out to be a major contributor to antibiotic stewardship.
In conclusion, PCT-guided antibiotic discontinuation in critically ill patients with sepsis 
could reduce the duration of antibiotic use and its costs with no apparent adverse outcomes 
in a country with a high prevalence of antimicrobial resistance and a national health 
insurance system.
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